How to interpret surrogate markers of efficacy in osteoporosis (multiple letters)

Journal of Bone and Mineral Research

Volumn 20, Issue 7, 2005, Pages 1261-1262

  Eastell, Richard ^a   Delmas, Pierre D ^b   Rosen, Clifford J ^c   Hochberg, Marc C ^d   Bonnick, Sydney Lou ^e   McClung, Michael ^f   Miller, Paul ^g   Broy, Susan ^h   Kagan, Risa ⁱ   Chen, Erluo ^j   Petruschke, Richard ^j   Thompson, Desmond E ^j   De Papp, Anne E ^j  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITÉ LYON 1   (France)

^c ST JOSEPH HOSPITAL   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e Clinical Research Center of North Texas   (United States)

^f OREGON OSTEOPOROSIS CENTER   (United States)

^g Health Sciences Center and Colorado Center for Bone Research   (United States)

^h ILLINOIS BONE AND JOINT INSTITUTE   (United States)

ⁱ Foundation for Osteoporosis Research and Education   (United States)

^j MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BIOLOGICAL MARKER; CALCIUM; RISEDRONIC ACID; VITAMIN D;

BONE DENSITOMETRY; BONE DENSITY; BONE TURNOVER; DISEASE MARKER; DRUG EFFICACY; FOLLOW UP; FRACTURE; HUMAN; LETTER; OSTEOPOROSIS; POSTMENOPAUSE; RISK ASSESSMENT; RISK FACTOR; STATISTICAL ANALYSIS;

EID: 20844459509     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/JBMR.050217     Document Type: Letter

References (0)